Axcella Health Inc. (NASDAQ:AXLA) has been assigned an average rating of “Buy” from the ten brokerages that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $16.43.
Separately, Wedbush reiterated a “buy” rating and set a $11.00 target price (down previously from $19.00) on shares of Axcella Health in a research note on Saturday, March 20th.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in Axcella Health by 2.1% during the 1st quarter. BlackRock Inc. now owns 1,040,976 shares of the company’s stock worth $4,955,000 after acquiring an additional 21,423 shares during the period. Geode Capital Management LLC increased its stake in shares of Axcella Health by 4.4% in the 1st quarter. Geode Capital Management LLC now owns 230,685 shares of the company’s stock valued at $1,098,000 after purchasing an additional 9,659 shares during the last quarter. Northern Trust Corp increased its stake in shares of Axcella Health by 9.7% in the 4th quarter. Northern Trust Corp now owns 189,806 shares of the company’s stock valued at $985,000 after purchasing an additional 16,839 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Axcella Health by 51.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 124,286 shares of the company’s stock valued at $591,000 after purchasing an additional 42,413 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Axcella Health by 148.8% in the 4th quarter. Bank of New York Mellon Corp now owns 87,116 shares of the company’s stock valued at $453,000 after purchasing an additional 52,100 shares during the last quarter. Hedge funds and other institutional investors own 66.77% of the company’s stock.
Axcella Health (NASDAQ:AXLA) last announced its earnings results on Wednesday, May 5th. The company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.02. Research analysts predict that Axcella Health will post -1.76 EPS for the current fiscal year.
About Axcella Health
Axcella Health Inc operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis.
Further Reading: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.